Sinopharm, the Chinese vaccine anti Covid-19, was approved by WHO for emergency use


gave emergency use of , the Chinese vaccine anti Covid-19. „The vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency,” said Director-General Tedros Adhahom Ghebreysus. The Chinese vaccine has already been exported by millions of doses in some countries. Medical regulators in the European Union, Britain and the United States have not examined the jab, which relies on relatively old vaccine technology. Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59, especially to prevent severe disease or symptomatic and hospitalized cases up to 79%.


The Vaccine Alliance, which co-runs COVAX, welcomed the announcement. “This means the world has yet another safe and effective tool in the fight against this pandemic,” the alliance said. Suerie Moon, co-director of the Global Health Program at Geneva’s Graduate Institute, said the WHO decision on the Sinopharm COVID-19 vaccine and other Chinese vaccines will “carry a lot of weight.” China has five shots in use, but the majority of its exports abroad come from two companies: Sinopharm and Sinovac. A decision on Sinovac is expected next week.